[1]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37-40.
 WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(12):37-40.
点击复制

基本药物可获得性影响因素研究
——基于25省监测点数据的实证分析
分享到:

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年12期
页码:
37-40
栏目:
药械管理
出版日期:
2018-12-04

文章信息/Info

Title:
Study on the Factors Affecting the Availability of Essential Drugs
——An Empirical Analysis Based on Data from 25 Provinces
作者:
吴玉霞1徐 伟1蔡功杰1杜雯雯1
1.中国药科大学国际医药商学院,江苏 南京 211198
Author(s):
WU Yu-xiaXU WeiCAI Gong-jieDU Wen-wen
School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing Jiangsu 211198,China
关键词:
基本药物可获得性药品短缺
Keywords:
essential medicines availability shortage of medicines
分类号:
R95
文献标志码:
A
摘要:
通过分析2016年7—12月25个省市基本药物短缺监测点数据,了解基本药物可获得性情况。结果显示:25个省市监测点短缺基本药物呈现大类集中、品种分散的特点,原料短缺、垄断所致的企业产能不足、采购制度形成的价格限制是基本药物短缺的主要原因;企业的逐利倾向与基本药物利润微薄之间的矛盾导致基本药物供应链环节中企业不规范、消极行为普遍。因此,应发挥政府主导作用,理顺基本药物供应链的利益矛盾,保障基本药物制度的顺利实施。
Abstract:
By analyzing the data of basic drug shortage monitoring points in 25 provinces and cities from July to December 2016,we can understand the current status of essential drug availability. The results showed that the shortage of essential drugs in 25 provinces and cities was characterized by large concentration and variety dispersion. The shortage of raw materials,the lack of production capacity caused by monopoly,and the price limit formed by the procurement system were the main reasons for the shortage of essential drugs. The contradiction between the favorable tendency and the meager profit of essential drugs has led to the non-standardization and negative behavior of enterprises in the essential drug supply chain. Therefore,we should give play to the leading role of the government,rationalize the conflicts of interest in the essential drug supply chain,and ensure the smooth implementation of the essential drug system.

参考文献/References:

[1] 姚强, 罗飞, 何露洋,等. 药品可及性视角下国家基本药物制度实施效果评价[J]. 中国医院管理, 2014, 34(3):60-62.
[2] 商金鑫, 郭志刚, 林其敏,等. 北京市基本药物可及性评价研究[J]. 中国卫生政策研究, 2016, 9(2):52-58.
[3] 林宇, 郭蓝, 许燕,等. 广东省25家基层医疗卫生机构实施国家基本药物制度及药品不良反应监测情况的调查分析[J]. 中国药房, 2014(20):1832-1835.
[4] 谢宁, 沈毅, 任金妹,等. 上海市青浦区公立医疗卫生机构基本药物可获得性的实证研究[J]. 中国药房, 2016, 27(24):3331-3334.
[5] 杨慧云. 山东省农村地区基本药物的可及性研究[D]. 山东大学, 2012.
[6] 裴泽军, 孙欣. 对国家基本药物集中采购价格政策的思考与建议[J]. 中华医院管理杂志, 2013, 29(7):304-306.

相似文献/References:

[1]何常楠,傅鸿鹏.20种基本药物的集中采购价格分析[J].卫生经济研究,2016,(08):44.
[2]赵 静.应用层次分析法优化基本药物遴选的研究[J].卫生经济研究,2016,(12):13.
[3]路 云,张闪闪,李世勇.江苏省基本药物制度实施效果评价与思考[J].卫生经济研究,2017,(10):45.
[4]王文杰,毛宗福,肖琳琪,等.贫困地区基层医疗机构基本药物供应保障研究[J].卫生经济研究,2018,(02):35.
[5]刘 昉,李翠翠,马 健,等.基层用药公平可及性评价研究[J].卫生经济研究,2018,(04):46.
[6]裴 婕,路 云,周 萍,等.瑞典基本药物目录的发展及启示[J].卫生经济研究,2018,(08):46.
 PEI Jie,LU Yun,ZHOU Ping,et al.The development and enlightenment of essential drug list in Sweden[J].Journal Press of Health Economics Research,2018,(12):46.
[7]杜雯雯,徐 伟,李孟林.南京市各级医疗机构用药结构和用药衔接性研究[J].卫生经济研究,2018,(09):26.
 DU Wen-wen,XU Wei,LI Meng-lin.Study on the Structure and Coherence of Drug Use in Medical Institutions at All Levels in Nanjing[J].Journal Press of Health Economics Research,2018,(12):26.
[8]杜雯雯,徐 伟,蔡功杰.我国基本药物全额保障的实现路径研究[J].卫生经济研究,2018,(12):40.
 DU Wen-wen,XU Wei,CAI Gong-jie.Study on the Realizing Path of the Full Guarantee of Essential Medicines in China[J].Journal Press of Health Economics Research,2018,(12):40.
[9]张闪闪,吴 天,张 冉,等.2018年版《国家基本药物目录》调整解读[J].卫生经济研究,2019,(06):47.
 ZHANG Shan-shan,WU Tian,ZHANG Ran,et al.Interpretation of the 2018 Edition of the National Essential Drugs List[J].Journal Press of Health Economics Research,2019,(12):47.
[10]李孟林,徐 伟,杜雯雯,等.我国上市专利药品可获得性实证研究[J].卫生经济研究,2019,(12):59.
 LI Meng-lin,XU Wei,DU Wen-wen,et al.Empirical Study on the Availability of Patented Drugs in China[J].Journal Press of Health Economics Research,2019,(12):59.

更新日期/Last Update: 2018-12-04